NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
About 62% of NeuBase Therapeutics' investor base is looking to short. The analysis of current outlook of investing in NeuBase Therapeutics suggests that many traders are alarmed regarding NeuBase Therapeutics' prospects. The current market sentiment, together with NeuBase Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use NeuBase Therapeutics stock news signals to limit their universe of possible portfolio assets.
NeuBase |
PITTSBURGH, Sept. 08, 2023 -- NeuBase Therapeutics, Inc. today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation and their subsequent press release issued on September 6, 2023. The NeuBase Board of Directors appreciates input from its shareholders. The Board remains committed to completing its comprehensive
Read at finance.yahoo.com
 |
NeuBase Therapeutics Fundamental Analysis
We analyze NeuBase Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
NeuBase Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
NeuBase Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuBase Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics with similar companies.
Peers
NeuBase Therapeutics Related Equities
| NAMS | NewAmsterdam Pharma | 41.41 | ||||
| CNSP | Cns Pharmaceuticals | 10.00 | ||||
| CMPX | Compass Therapeutics | 7.88 | ||||
| ZVSA | ZyVersa Therapeutics | 3.92 | ||||
| PHGE | Biomx | 1.59 | ||||
| IVA | Inventiva | 0.38 | ||||
| CGEM | Cullinan Oncology | 1.18 | ||||
| SONN | Sonnet Biotherapeutics | 5.71 | ||||
| GLUE | Monte Rosa | 7.45 | ||||
| IMMX | Immix Biopharma | 13.78 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |